Rid­ing on pos­i­tive PhI­II NASH da­ta, Madri­gal rais­es $300M for road to FDA

Madri­gal Phar­ma­ceu­ti­cals isn’t wast­ing any time cap­i­tal­iz­ing on its big NASH win, haul­ing in more than $300 mil­lion to push the pro­gram for­ward.

The biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER